Pratibha Desai, MD
Hematology & Oncology · Saint Petersburg, FLNPI 1861488454
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Seagen Inc. at 28.5% of the total. Reporting peaked in 2023 at $15,565 and has fallen 71.0% since, to $4,509 in 2025.
Across 1,031 payments — averaging $35.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$10K
- Pharmacosmos Therapeutics Inc.$3K
- AstraZeneca$2K
- Puma Biotechnology, Inc.$2K
- Novartis$2K
- Johnson & Johnson$1K
- plus $15K from 54 others
Across 338 payments — averaging $5980.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- Regeneron$420K
- Kyowa Kirin, Inc.$162K
- Servier Bioinnovation$137K
- Institut DE Recherches Internationales Servier$68K
- Mirati Therapeutics, Inc.$61K
- plus $169K from 8 others
What the payments were for
- Consulting fees$11,15831%
- Speaking & faculty fees$2,3006%
- Travel & lodging$1,1343%
- Food & beverage$20,43757%
- Education$1,1283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,156 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 77 | $952,167 |
| JakafiRuxolitinib Phosphate | 48 | $772,604 |
| ProcritEpoetin Alfa | 243 | $729,699 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 68 | $623,228 |
| CalquenceAcalabrutinib Maleate | 41 | $545,237 |
| ErleadaApalutamide | 38 | $521,571 |
| PromactaEltrombopag Olamine | 27 | $351,015 |
| GazyvaObinutuzumab | 20 | $324,013 |
| PomalystPomalidomide | 13 | $292,240 |
| ImbruvicaIbrutinib | 17 | $271,366 |
| KisqaliRibociclib Succinate | 24 | $265,594 |
| ScemblixAsciminib Hydrochloride | 11 | $231,685 |
| SprycelDasatinib | 13 | $227,717 |
| RuxienceRituximab-Pvvr | 35 | $213,693 |
| IbrancePalbociclib | 13 | $208,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonProcrit, Erleada, Xarelto | $1,396 | $1,274,594314 claims |
| NovartisPromacta, Kisqali, Scemblix | $1,880 | $848,29462 claims |
| Incyte CorporationJakafi | $378 | $772,60448 claims |
| AstraZenecaCalquence, Imfinzi | $2,017 | $718,27255 claims |
| PfizerRuxience, Ibrance, Retacrit, Octagam, Nivestym | $1,119 | $658,023191 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $568 | $519,95726 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $90 | $271,36617 claims |
| Lilly USA, LLCVerzenio | $985 | $173,29412 claims |
| AmgenProlia, Neupogen | $594 | $79,67450 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $371 | $78,35026 claims |
| AbbVieLupron Depot | $443 | $47,16624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Saint Petersburg
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.